Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
News|Articles|November 15, 2017
- Pharmaceutical Technology-11-15-2017
- Volume 2017 ebook
- Issue 2
Cold Chain: Delivering Vaccines to Patients
Author(s)Amber Lowry
This article explores some of the challenges, services, and technologies that go into ensuring that vaccines are properly temperature controlled and maintain product integrity for delivery to patients.
Advertisement
With advancement in vaccine development comes an urgency to optimize the cold-chain delivery of these increasingly condition-sensitive biological products. This sensitivity has added new degrees of complexity to already complex supply chains and global regulations, resulting in the need for more precise approaches toward transporting vaccines.
Download the
.
Article Details
Pharmaceutical Technology and BioPharm International
eBook: Vaccine Development and Manufacturing 2017
November 2017
Pages: 46–49
Citation
When referring to this article, please cite it as A. Lowry, " Cold Chain: Delivering Vaccines to Patients," Pharmaceutical Technology and BioPharm International Vaccine Development and Manufacturing 2017 eBook (November 2017).
Articles in this issue
almost 9 years ago
Therapeutic Vaccines Target Cancer and Other Viral-Induced Diseasesalmost 9 years ago
Designing and Operating Flexible, High-Containment Vaccine Manufacturingalmost 9 years ago
Using Human Challenge Trials to Develop Flu Vaccinesalmost 9 years ago
Making Vaccines Accessiblealmost 9 years ago
Moving to Closed Systems for Aseptic Processingalmost 9 years ago
Accelerating Vaccine Development and ManufacturingAdvertisement
Related to this article
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Jason Bertola, executive director of Commercial Development for the Advanced Synthesis Platform at Lonza in North America, explains the demand for spray drying and the hurdles involved with scale up, in an interview with PharmTech.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
3
Complying with International Pharmacopoeias
4
CPHI Milan: Packaging and Delivery Decisions Must Reflect Real-World Care
5